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The role of unconventional myosins in neuroendocrine cells is not fully understood, with involvement suggested in the
movement of both secretory vesicles and mitochondria. Here, we demonstrate colocalization of myosin Va (MyoVa) with
insulin in pancreatic -cells and show that MyoVa copurifies with insulin in density gradients and with the vesicle
marker phogrin-enhanced green fluorescent protein upon fluorescence-activated sorting of vesicles. By contrast, MyoVa
immunoreactivity was poorly colocalized with mitochondrial or other markers. Demonstrating an important role for
MyoVa in the recruitment of secretory vesicles to the cell surface, a reduction of MyoVa protein levels achieved by RNA
interference caused a significant decrease in glucose- or depolarization-stimulated insulin secretion. Similarly, expression
of the dominant-negative–acting globular tail domain of MyoVa decreased by50% the number of vesicles docked at the
plasma membrane and by 87% the number of depolarization-stimulated exocytotic events detected by total internal
reflection fluorescence microscopy. We conclude that MyoVa-driven movements of vesicles along the cortical actin
network are essential for the terminal stages of regulated exocytosis in -cells.
INTRODUCTION
Glucose and other stimuli cause large dense core insulin-
containing vesicles (LDCVs) to move toward, and eventu-
ally fuse reversibly with, the plasma membrane in pancre-
atic islet -cells (Rutter, 2001, 2004). We have recently shown
that insulin-containing vesicles are transported from the cell
center to the cortex primarily on the microtubule (MT)-
based motor protein conventional kinesin, also called kine-
sin I (Varadi et al., 2002, 2003). By contrast, the short-range
movements in the cortical regions of the cell that carry
vesicles over the last few hundred nanometers to the cell
surface seem more likely to involve F-actin, which is abun-
dant in this region (Nakata and Hirokawa, 1992; Varadi et
al., 2003; Tsuboi et al., 2003). Prime candidates for transport
along these filaments are class V myosin motors (Mermall et
al., 1998; Rudolf et al., 2003). Myosin Va (MyoVa) is com-
posed of two heavy chains that dimerize via a coiled-coil
motif located in the stalk region of the heavy chain (Cheney
et al., 1993). The heavy chain contains an amino-terminal,
actin-binding motor domain (Cheney et al., 1993) followed
by a neck region to which up to six regulatory light chains
are bound, and a carboxy-terminal globular domain
(Cheney et al., 1993) that is thought to mediate organelle
binding specificity (Reck-Peterson et al., 2000).
Insight into the potential functions of MyoVa has come
from several lines of investigation, including identification
of organelles and proteins that interact with MyoVa (Reck-
Peterson et al., 2000; Karcher et al., 2002; Langford, 2002). The
most powerful strategy has been the phenotypic character-
ization of lethal alleles of the dilute (MyoVa lethal mutant)
mouse and cells derived from them (Mercer et al., 1991). The
dilute mice develop severe seizures and die within 3 wk after
birth. The primary neuronal defect thought be responsible is
the absence of smooth endoplasmic reticulum within the
dendritic spines of Purkinje neurons (Takagishi et al., 1996).
Analyses of organelle movement in cultured melanocytes
(Provance et al., 1996; Wu et al., 1998), neurons (Bridgman,
1999) and macrophages (Al Haddad et al., 2001) from dilute
and wild-type mice also have provided evidence for a direct
role of MyoVa in both organelle transport and tethering.
Moreover, MyoVa has been identified on synaptic vesicles
(Evans et al., 1998; Miller and Sheetz, 2000), and inhibition of
myosin ATPase activity reduces neurotransmitter release in
brain slices (Prekeris and Terrian, 1997). In addition, a recent
report revealed the role of MyoVa in the distribution of
secretory granules in PC12 cells (Rudolf et al., 2003). Finally,
the yeast homologue of MyoV, Myo2p, is involved in secre-
tory vesicle (Schott et al., 1999), peroxisome (Hoepfner et al.,
2001), and vacuole (Ishikawa et al., 2003) transport.
The role of MyoVa in mitochondrial transport is, however,
less clear. In vitro motility assay demonstrated that actin-
dependent motor activity is associated with mitochondria
(Simon et al., 1995). Immunoelectron microscopy revealed
association of MyoVa with the mitochondrial membrane in
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melanoma cells (Nascimento et al., 1997). Furthermore, a
recent study also described the presence of this motor pro-
tein on mitochondria in myoblasts and suggested a role for
MyoVa in calcium-dependent movements of these or-
ganelles (Yi et al., 2004). In contrast, mitochondrial transport
was not affected in cells bearing mutations in either of the
genes for myosins I, II, and V (DePina and Langford, 1999),
and a shortening of the lever arm of Myo2p had no effect on
mitochondrial morphology, actin organization, or the rate of
mitochondrial movement in the mother cell (Boldogh et al.,
1998). On the other hand, Myo2p mutant cells were defective
in the segregation of mitochondria (Boldogh et al., 1998,
2004; Itoh et al., 2002).
Myosin Va is recruited to the vesicle surface by members
of the Rab family of G proteins (Fukuda et al., 2002; Hume et
al., 2002; Provance et al., 2002, Wu et al., 2002b). This process
requires the presence of a rabphilin-like effector protein that
bridges the indirect interaction between the Rab protein and
myosin Va (Wu et al., 2002a; Fukuda et al., 2002). In mela-
nocytes, Rab27a binds to the melanosome first and then
recruits melanophilin/Slac-2a, a rabphilin-like effector pro-
tein, which in turn recruits myosin Va (Fukuda et al., 2002;
Wu et al., 2002a,b). In pancreatic -cells, suppression of
Rab27a function impaired insulin exocytosis triggered by
secretagogues (Waselle et al., 2003). The -cells also express
a Rab27a effector protein granuphilin-a/SLP4-a, which is
localized on the membrane of insulin granules (Wang et al.,
1999; Yi et al., 2002; Izumi et al., 2003), and its overexpression
causes a profound inhibition of depolarization-induced in-
sulin secretion (Wang et al., 1999; Coppola et al., 2002; Torii
et al., 2002). Granuphilin directly binds to syntaxin 1a (Torii
et al., 2002, 2004) and Munc 18-1 (Coppola et al., 2002) and is
thought to be involved in tethering insulin granules to the
plasma membrane (Torii et al., 2004). MyRIP/Slac2c, another
Rab27a effector (Kuroda et al., 2002), is also expressed in
-cells and involved in the regulation of insulin release
(Waselle et al., 2003). However, unlike for Rab27 or its effec-
tor proteins, the role of MyoVa in insulin-containing vesicle
transport and membrane fusion is not known.
Here, we investigated the involvement of MyoVa in the
distribution, motility, and exocytosis of insulin-containing
vesicles in single pancreatic -cells (MIN6). Inhibition of
MyoVa function achieved by RNA interference or overex-
pression of a dominant-negative mutant resulted in cluster-
ing of secretory granules, a substantial reduction in the
number of vesicles docked at the plasma membrane, and a
decrease in the number of single exocytotic events and in
global insulin release. These data demonstrate that MyoVa is
essential for trafficking secretory organelles in neuroendo-
crine cells.
MATERIALS AND METHODS
Materials
Cell culture reagents were from Invitrogen (Life Science Research, Paisley,
United Kingdom), and all molecular biologicals were from Roche Diagnostics
(Lewes, United Kingdom). Alexa Fluor goat anti-rabbit or anti-guinea pig 488
and 568 secondary antibodies and Alexa Fluor 488-phalloidin were from
Molecular Probes (Eugene, OR). Mouse monoclonal anti--tubulin was ob-
tained from Sigma Chemical (Poole, Dorset, United Kingdom). Rabbit poly-
clonal anti-myosin Va antibody, DIL2, was raised against a glutathione S-
transferase (GST)-fusion protein containing myosin V heavy chain residues
910-1106, which correspond to the first segment of -helical coiled-coil in the
central rod domain (Wu et al., 1998).
Cell Culture
MIN6 pancreatic -cells (passages 19–35) were cultured in DMEM supple-
mented with 15% (vol/vol) fetal calf serum, 100 U ml1 penicillin, 0.1 mg
ml1 streptomycin, and 2 mM l-glutamine at 37°C in an atmosphere of
humidified air (95%) and CO2 (5%) as described previously (Molnar et al.,
1995).
Plasmids
A plasmid encoding mitochondrially targeted Discoideum red fluorescent
protein (Mito.DsRed) was generated as described previously (Varadi et al.,
2002). The expression vector myosin Va globular tail domain (MGTD).pEGFP
was described previously (Wu et al., 1998). Plasmid encoding neuropeptide Y
(NPY)-targeted monomeric red fluorescent protein (NPY-mRFP) was gener-
ated as described previously (Tsuboi et al., 2003).
RNA Preparation, Reverse Transcription, and PCR
Total RNA from mouse brain, spleen, and MIN6 pancreatic -cells was
prepared as described previously (Varadi et al., 1996). The total RNA (3 g)
was reverse transcribed at 42°C for 60 min in 50 l of reaction mixture
containing 1 reverse transcriptase buffer (50 mM Tris-HCl, pH 8.3, 40 mM
KCl, 1 mM dithiothreitol [DTT], and 6 mM MgCl2) containing 1.25 g of
oligo(dT), 0.5 mM each dNTP, 10 mM DTT, 40 U of rRNasin, and 500 U of
Moloney murine leukemia virus reverse transcriptase. One-tenth of the cDNA
was subjected to a PCR in 50-l reaction mixture containing 1 PCR buffer (50
mM KCl, 10 mM Tris-HCl, pH 9.0, and 5 mM DTT), which contained 2 or 4
mM MgCl2, 0.1 mM each dNTP, 20 pmol of each primer, and 0.5 U of Taq
DNA polymerase (Promega, Madison, WI). PCR was carried out in a pro-
grammable thermal controller (PTC-100; MJ Research, Essex, United King-
dom) at 95°C for 2 min followed by 30 cycles at 95°C for 1 min, 53°C for 1 min,
and 72°C for 1 min. The last cycle was followed by a final extension step at
72°C for 10 min. After PCR, the samples were subjected to electrophoresis in
a 1.9% (wt/vol) agarose gel containing 0.4 g of ethidium bromide in 1 TBE
buffer (89 mM Tris base, 89 mM boric acid, and 2 mM EDTA). For DNA
sequencing and restriction enzyme digestion, 100-l PCR samples were pre-
cipitated with ethanol and then fractionated by electrophoresis in 1.3% (wt/
vol) low melting point agarose gels. The separated bands were isolated, and
the PCR products were extracted from the gel slices by Wizard PCR preps
DNA purification system (Promega). The primers were designed to flank the
alternative spliced forms in the C-terminal tail domain of MyoVa (Seperack et
al., 1995). The following forward 1) 5-CGAGCTGAATGAGTTGCGC-3, nu-
cleotides 3700–3718; 2) 5-CATCTTGAGGTCGCAGCTGG-3, nucleotides
3841–3860; and reverse 3) 5-GATATGTTCTCCATCTGCC-3, nucleotides
4371–4389; 4) 5-GCTCATCGATGATCTCTCCTG-3, nucleotides 4392–4412,
primers were used. Numbers correspond to MyoVa cDNA accession number
NM_010864. We used these primers in combinations (1–3, 1–4, 2–3, and 2–4),
and all PCR reactions resulted in identical alternative spliced forms in all
samples tested. PCR amplification of MyoVa with primers 1 and 3 are shown
on Figure 1A. The following controls were used to check for possible ampli-
fication of contaminant DNA and RNA by PCR: RNA blanks taken through
the cDNA step in the absence of reverse transcriptase were used in every PCR
reaction and for each set of primers; samples without templates were run for
every primer pair for each PCR experiment.
Live Cell Imaging and Immunocytochemistry
Cells were cotransfected with 1 g of plasmids encoding 1) MGTD.EGFP and
NPY.mRFP, 2) MGTD.EGFP and Mito.DsRed; or 3) empty vectors (pAdTrack-
CMV, the latter encodes enhanced green fluorescent protein [EGFP]) (He et al.,
1998), by using 10 g ml1 LipofectAMINE in Opti-MEM I medium (Invitro-
gen) for 4 h. For live imaging, a Nipkov disk-based UltraVIEW confocal
system (PerkinElmer Life and Analytical Sciences, Boston, MA) was used at
2–4 Hz for 100 s (200–400 frames in total) in Krebs-Ringer-HEPES (KRH)
bicarbonate buffer composed of 140 mM NaCl, 3.6 mM KCl, 0.5 mM
NaH2PO4, 0.5 mM MgSO4, 2.0 mM NaHCO3, 16–30 mM glucose, 10 mM
HEPES, pH 7.4, and 1.0 mM CaCl2 equilibrated with O2/CO2 [95:5 (vol/vol)]
at 37°C. Immunocytochemistry was performed as described previously
(Varadi and Rutter, 2002), and then images were captured on an UltraVIEW
confocal microscope (Varadi et al., 2004).
Total Internal Reflection Fluorescence (TIRF) Microscopy
Cells were imaged in KRH bicarbonate buffer initially at 3 mM and then at 30
mM glucose. Incubations were performed on a thermostatically controlled
(37°C) stage of an Olympus IX-70 microscope (Olympus UK, London, United
Kingdom) fitted with a high numerical aperture objective lens (Apochromatic,
100, 1.65 numerical aperture, infinity corrected; Olympus UK). To assess the
dynamics of NPY.mRFP, we used a TIRF microscope (Till Photonics, Munich,
Germany) as described previously (Tsuboi et al., 2000; Pinton et al., 2002;
Tsuboi and Rutter, 2003). Images were captured at 2 Hz with a cooled
charge-coupled device camera (640  480 pixels, IMAGO; Till Photonics)
controlled by TillvislON software. Image analysis was performed with Meta-
Morph software (Universal Imaging, Downingtown, PA).
Measurement of Intracellular Free Ca2 Concentration
[Ca2]i
Changes in [Ca2]i were measured at 37°C with entrapped Fura-2 (Grynk-
iewicz et al., 1985) by using a Leica DM-IRBI inverted microscope (40
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objective) and a Hamamatsu C4742-995 charged-coupled device camera
driven by OpenLab software (Improvision, Coventry, United Kingdom)
(Varadi and Rutter, 2002).
Silencing of Endogenous Myosin Va Expression with
Small Interfering RNAs (siRNAs)
Sequences corresponding to the mouse myosin Va cDNA (Strobel et al., 1990)
2390–2410, 5-AAGAGATACCTGTGTATGCAG-3; and 2507–2528, 5-AAG-
TACTGGCGCATGTATGTG-3) were used as targets for siRNA. The follow-
ing siRNAs were used as controls: 5-AAGTGTGCAACCATGTGAATG-3
and 5-AAGTGGTTGGCGATTACCGAT-3. These sequences showed no sig-
nificant homology to any other gene known analyzed using BLAST search.
siRNAs were synthesized by in vitro transcription by using the Silencer
siRNA construction kit (Ambion, Austin, TX). MIN6 cells were transfected
with 60 pmol of siRNA duplex by using 3 l of Oligofectamine (Invitrogen)
in growth medium without antibiotics or serum for 5 h (Varadi et al., 2003).
Whole cell lysate was prepared 24, 48, 72, and 96 h after transfection. Cell
lysate (10 g) from siRNA and control RNA-transfected cells were separated
on a 9% polyacrylamide gel and then blotted onto Immobilon-P transfer
membrane and probed with a rabbit polyclonal anti-myosin Va antibody and
a mouse monoclonal anti-tubulin antibody. The blots were scanned and
quantified with NIH ImageJ software (http://rsb.info.nih.gov/ij/).
Assay of Insulin Release
MIN6 cells were seeded at a density of 4–6  105 ml1 on 24-mm-diameter
poly-l-lysine–coated coverslips and cultured overnight. Cells were trans-
fected with siRNAs as described above. The cells were cultured for 48 h, and
insulin release was stimulated and assayed as described previously (Varadi et
al., 2002) using Mercodia ultrasensitive mouse insulin enzyme-linked immu-
nosorbent assay (ELISA) kit (Mercodia AB, Uppsala, Sweden).
Subcellular Fractionation by Using OptiPrep Density
Gradient Centrifugation
Cells were homogenized in a buffer containing 0.3 M sucrose, 1 mM EDTA, 1
mM MgSO4, 10 mM MES-NaOH, pH 6.5, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF), 5 g ml1 aprotinin, and 5 g ml1 leupeptin by using a
ball-bearing homogenizer and then centrifuged at 500  g for 10 min. The
postnuclear supernatant was layered on top of a continuous 8–19% (wt/vol)
OptiPrep gradient obtained using a Gradient Master (BioComp Instruments,
Fredericton, New Brunswick, Canada) and centrifuged at 16,000  g for 16 h.
Gradient fractions were collected by downward displacement (Gradient sta-
tion; BioComp Instruments).
Fluorescence-activated Cell Sorting (FACS) of Vesicles and
Precipitation with Trichloroacetic Acid (TCA)
MIN6 cells were infected with the recombinant phogrin.EGFP adenoviral
construct at a multiplicity of 30–100 viral particles/cell, for 1 h. Cells were
subsequently used 24 h postinfection when 95% of cells were infected. Cells
were scraped into ice-cold buffer containing 10 mM 3-(N-morpholino)pro-
panesulfonic acid (MOPS), 260 mM sucrose, pH 6.5, 1 mM PMSF, 5 g ml1
aprotinin, and 5 g ml1 leupeptin and then homogenized with a Teflon
homogenizer and centrifuged at 500  g for 5 min. The postnuclear super-
natant was resuspended in MOPS buffer to a concentration of 1–2 mg ml1
and sorted into two fractions: particles labeled with EGFP and unlabeled
organelles. Sorting was carried out on a FACS Vantage sorter (BD Biosciences,
San Jose, CA) fitted with a 488-nm argon ion laser. The EGFP fluorescence was
measured using a band pass filter at 530/30 nm. Vesicles (7  106) were
obtained following sorting. Vesicles (7 104) were seeded onto poly-l-lysine–
coated coverslips and used for immunocytochemistry. The remaining vesicle
suspension was treated with equal volume of 20% (vol/vol) TCA for 30 min
at 4°C and then centrifuged at 13,000  g for 10 min. The pellet was washed
twice with cold acetone and then dried. The proteins were separated on
SDS-gels.
Statistical Analysis
Data are presented as the mean  SEM for the number of observations given,
and statistical significance was calculated using an unpaired Student’s t test.
RESULTS
Myosin Va Is Expressed in Clonal MIN -Cells and Is
Associated with Insulin-containing Vesicles
Insulin-containing vesicles undergo short (non-Brownian)
movements in the F-actin–rich cell cortex in clonal MIN6
pancreatic -cells (Tsuboi et al., 2003). To investigate
whether this movement might involve F-actin–dependent
transport via myosin motors, we investigated the presence
of unconventional MyoVa on insulin-containing LDCVs.
First, we investigated the expression of MyoVa mRNA in
MIN6 -cells by using reverse transcription (RT)-PCR. A
strategy was used by which the four different alternatively
spliced isoforms of MyoVa could be identified (Figure 1A;
-BDF, -BD-F, -B-DF, and B-D-F). Spleen is known
to express three splice variants of MyoVa (Figure 1A;
-BDF, -BD-F, -B-DF; Seperack et al., 1995; Huang et
al., 1998a,b; Au and Huang, 2002). The forth and shortest
splice form, excluding both exons D and F,‘ is expressed in
Figure 1. MyoVa is expressed in MIN6 cells and colocalized with
insulin-containing vesicles. (A) The different alternative spliced
forms of MyoVa were amplified by PCR. The structure of the
possible alternative spliced forms is shown at the top. The capital
letters represent exons as described previously (Seperack et al.,
1995). The bold arrows represent the primer set used in RT-PCR
amplification. Agarose gels show the MyoVa and -actin amplifi-
cation products from brain, spleen, and MIN6 cells. (B) Homoge-
nates from MIN6 and primary rat pancreatic islet cells were pre-
pared and proteins separated on by SDS gel chromatography (see
Materials and Methods). Immunoblots were probed with a rabbit
polyclonal anti-MyoVa antibody (DIL2, 1:5000 dilution). (C) MIN6
cells were fixed and coimmunostained with a rabbit polyclonal
anti-MyoVa (1:1000 dilution) and a guinea pig polyclonal anti-
insulin (1:1000 dilution) primary antibody then visualized with an
Alexa Fluor goat anti-guinea pig 568 (a) and an Alexa Fluor goat
anti-rabbit 488 (b) secondary antibody, respectively. (c) Overlay of a
and b. Arrows indicate colocalization of insulin and MyoVa on
individual vesicles. Hatched boundaries obtained from overlay with
the transmitted image of the cell, indicate the cell periphery.
Zoomed in regions are shown on the inserted images.
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brain (Figure 1A; B-D-F; Seperack et al., 1995; Huang et al.,
1998a,b ; Au and Huang, 2002). Similar to brain and other
neuroendocrine cells (Seperack et al., 1995; Nagashima et al.,
2002; Wu et al., 2002b), MIN6 -cells expressed only the
B-D-F splice variant (Figure 1A). Immunoblot analysis
revealed that MyoVa is present at the protein level in both
MIN6 -cells and primary rat islets of Langerhans (Figure
1B). By using double-immunofluorescent microscopy,
MyoVa was localized principally on insulin-positive struc-
tures in both MIN6 cells (Figure 1C, zoomed in regions,
arrowheads) and in primary rat -cells (our unpublished
data).
To assess the proportion of cellular MyoVa that was stably
associated with LDCs, we next explored the behavior of
MyoVa and other organelle markers upon density gradient
fractionation of extracts from clonal MIN6 -cells. Secretory
granules were enriched from the postnuclear supernatant by
differential centrifugation and subsequently loaded onto a
continuous OptiPrep density gradient to separate the vesic-
ular components according to their buoyant density. The
obtained gradient fractions were analyzed by immunoblot-
ting to determine the distribution of MyoVa (Figure 2A,
MyoVa), glycerol phosphate dehydrogenase (mGPDH; a
marker protein for mitochondria; Figure 2A), phogrin
(LDCV membranes) (Wasmeier and Hutton, 1996; Pouli et
al., 1998); trans-Golgi network protein 38 (TGN38; Golgi)
(Luzio et al., 1990); insulin receptor (plasma membrane
[PM]); mannose-6-phosphate receptor (lysosomes), and ste-
rol regulatory element binding protein 1c precursor (endo-
plasmic reticulum [ER]; Varadi and Rutter, unpublished
data) (Brown and Goldstein, 1997). The distribution of var-
ious organelles detected with organelle-specific antibodies,
or by the measurement of insulin content of each fraction, is
indicated in Figure 2A. By this approach, the peak of MyoVa
immunoreactivity (Figure 2A, fractions 9–12) coincided
closely with that of insulin (Figure 2A, fractions 10–12) and
of the vesicle transmembrane protein phogrin (fractions 10–
12; our unpublished data). In contrast, only a very small
proportion of the total MyoVa immunoreactivity was found
in the cytosolic (Figure 2A, fractions 1–4), ER (Figure 2A,
fractions 2 and 3), mitochondrial (Figure 2A, fractions 13–
15), or other fractions.
Because the lighter insulin-containing fractions also pos-
sessed Golgi-derived membranes, we sought further to dem-
onstrate the association of MyoVa with insulin-containing
vesicles by FACS phogrin-EGFP–labeled vesicles. Phogrin-
EGFP provides an efficient and selective tag for LDCVs, as
demonstrated by the close (95%) colocalization of phogrin-
EGFP and insulin in this cell type (Pouli et al., 1998; Varadi
et al., 2002; Tsuboi and Rutter, 2003). FACS-purified pho-
grin-EGFP–labeled particles were positive for both insulin
(Figure 2B, a–c) and MyoVa (Figure 2B, d–f), and the appar-
ent dimensions of the doubly labeled structures (200–500
nm) corresponded closely with those of dense-core secretory
vesicles (Figure 2B) (Bonner-Weir, 1988), at least at the limit
of light microscopy. To eliminate the possibility that the
MyoVa antibody nonspecifically cross-reacted with insulin
when used for immunocytochemistry, we precipitated the
FACS-sorted vesicles with trichloroacetic acid, immuno-
blotted, and then probed with the MyoVa-specific antibody.
This antibody recognized MyoVa with the correct molecular
weight in these samples (Figure 2B, arrow). Together, the
three complimentary approaches used above support the
view that the majority of MyoVa is associated with insulin-
containing granules in -cells.
Expression of the MyoVa Tail Domain Leads to
Clustering of Insulin-containing Vesicles
To test whether inhibition of the motor activity of MyoVa
leads to reduction in motility and distribution of insulin-
Figure 2. MyoVa is associated with insulin-containing vesicle frac-
tion. (A) MIN6 cell homogenates were fractionated by OptiPrep
density gradient centrifugation and the insulin content in each
fraction was determined (see Materials and Methods). The same sub-
cellular fractions were separated by SDS gel electrophoresis and the
immunoblots probed with a rabbit polyclonal anti-MyoVa antibody
(1:5000 dilution) or with a rabbit polyclonal anti-glycerol phosphate
dehydrogenase (mGPDH, 1:1000 dilution) antibody. The latter was
used to detect mitochondria. The amount of insulin and mGPDH
was normalized to the protein content in each fraction. The contin-
uous and dotted lines represent the Gaussian distribution of insulin
and mGPDH, respectively. Distribution of various organelles in
each fraction detected by organelle specific antibodies (see Materials
and Methods for details) is indicated at the bottom. Cyt., cytosol; Lys.,
lysosomes SG, secretory granules (LDCVs); Mit., mitochondria. (B)
MIN6 cells were infected with the recombinant phogrin.EGFP ad-
enoviral construct and fluorescent EGFP-labeled vesicles were sep-
arated from nonlabeled organelles by FACS sorting. The sorted
vesicle proteins (8  106 fluorescent particles) were precipitated
with TCA and then separated on a SDS gel. The immunoblot was
probed with the rabbit polyclonal anti-MyoVa antibody (1:5000
dilution). Arrow on the left indicates the presence of MyoVa in the
cell homogenate (Hom.) and the FACS sorted vesicles (FACS vesi-
cles). FACS sorted vesicles were seeded onto poly-l-lysine–coated
coverslips and immunostained with a guinea pig anti-insulin anti-
body or a rabbit polyclonal anti-MyoVa antibody then visualized
with an Alexa Fluor goat anti-guinea pig 568 (a) and an Alexa Fluor
goat anti rabbit 568 (b) secondary antibody, respectively. (a and d)
Phogrin.EGFP fluorescence. (c and f) Overlay of a and b and d and
e, respectively.
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containing vesicles, we transfected a C-terminal tail frag-
ment of MyoVa, MGTD.EGFP, into -cells. This tail frag-
ment is known to act as a potent inhibitor of MyoVa function
in mouse melanocytes (Wu et al., 1998) and PC12 cells (Ru-
dolf et al., 2003). We labeled insulin-containing vesicles by
expressing cDNA encoding neuropeptide Y fused to mono-
meric red fluorescent protein (NPY.mRFP), a construct that
is targeted efficiently to LDCVs (Tsuboi and Rutter, 2003).
Whereas in control cells labeled secretory vesicles were
evenly distributed and frequently seen at the cell periphery
(Figure 3, a–d), expression of the MyoVa tail fragment led to
vesicle clustering and exclusion from the cell cortex (Figures
3, e–h, and 4, a–d). If MGTD.EGFP directly interacted with
secretory granules, then we expected to observe an in-
creased local concentration of MGTD.EGFP in the clusters of
fluorescent secretory vesicles. As anticipated, MGTD.EGFP
also showed strong clustering (Figure 3f) and high, although
not complete, colocalization with the accumulated red fluo-
rescence of vesicles (Figure 3, g and h). The observed for-
mation of clusters is likely to involve both a block of trans-
port of LDCVs to the actin cortex and/or a change in
tethering. Both phenomena have previously been observed
for melanosomes in melanocytes expressing the tail frag-
ment of MyoVa and are also apparent in melanocytes from
dilute mice that carry a homozygous mutation in the MyoVa
gene (Wu et al., 1998).
In cells where more moderate clustering was apparent, we
were able to show clear colocalization of single vesicles with
MGTD.EGFP (Figure 4A, a–d, and Fig 4Acvideo1.mov). Al-
though it was not feasible to analyze individual vesicle
movements in cells where intense clustering was seen (Fig-
ure 3), this was possible in cells with moderate vesicle clus-
tering. As shown in Figure 4B (Fig 4Bvideo2.mov), vesicles
frequently moved together with the MGTD.EGFP, strongly
suggesting that MGTD.EGFP was bound to vesicles.
Impact of MyoVa Inhibition on Mitochondrial Movements
and the Cytoskeleton
In contrast to the situation with LDCVs, coexpression of
MGTD.EGFP with Mito.DsRed did not induce any cluster-
Figure 4. MGTD colocalizes and moves
with secretory granules. MIN6 cells were co-
transfected with NPY.mRFP and MGT-
D.EGFP and then imaged on the UltraVIEW
life cell confocal imaging system at 4 Hz. (a)
NPY.mRFP fluorescence. (b) MGTD.EGFP
fluorescence. (c) Overlay of a and b. (B, d)
Zoomed in regions in c, as indicated. (B)
Movements of NPY.mRFP and MGT-
D.EGFP were imaged sequentially with a
250-ms delay between channels. The veloc-
ity of both structures was calculated using
the image analysis software MetaMorph
(Universal Imaging) and is shown on the
images. Indicated by the red and green ar-
rowheads is a single NPY.mRFP-labeled
vesicle and MGTD.EGFP, respectively. The
original starting position is indicated with a
white asterisk. Direction of movement is la-
beled by yellow arrows (see Supplemental Data
Fig 4Acvideo1.mov and Fig 4Bvideo2.mov). (C)
MIN6 cells were cotransfected with 1 g of
MGTD.EGFP or the empty vector pAdTrack.
CMV and 0.25 g of Mito.DsRed and 24 h later
imaged on the UltraVIEW live cell confocal im-
aging system at 4 Hz. (a and d) EGFP fluores-
cence. (b and e) Mito.DsRed fluorescence. (c
and f) Overlay of a and b and d and e, respec-
tively. Boxed regions on b, d, and e are enlarged in C. (D) Indicated by a red arrowhead is a single moving mitochondrion (1 and 2) or MGTD.EGFP
(3) whose original starting position is labeled with a yellow asterisk (see Supplemental Data Fig 4Acvideo1.mov and Fig 4Bvideo2.mov).
Figure 3. Overexpression of MGTD inhibits
cortical localization of secretory granules and
induces the formation of secretory granule
clusters. MIN6 cells were cotransfected with
NPY.mRFP and MGTD.EGFP or the empty
plasmid pAdTrack.CMV and then imaged on
the UltraVIEW live cell confocal imaging sys-
tem (see Materials and Methods for details). (a
and e) NPY.mRFP fluorescence. (b and f)
EGFP fluorescence. (c and g) Overlay of a
and b and e and f, respectively. (d and h)
Zoomed in regions in c and g, respectively.
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ing of mitochondria (Figure 4C) and the majority of the
expressed MGTD.EGFP failed to localize with these or-
ganelles (Figure 4C, d–f). Moreover, the movement of indi-
vidual mitochondria was not affected by expression of MGT-
D.EGFP (Figure 4, D and C). Thus, rapid movements of
MGTD.EGFP were observed that did not coincide with those
of the separately labeled mitochondria (Figure 4D).
To eliminate the possibility that the clustering of LDCVs
may be due to altered organization of actin filaments and/or
microtubules, we visualized these cytoskeletal structures in
control and MGTD.EGFP-expressing cells. As anticipated
given the normal mitochondrial distribution and motility,
no apparent effect of MGTD.EGFP was observed on the
structure and organization of actin and tubulin networks
(our unpublished data). In MIN6 cells, strong phalloidin
staining was observed predominantly at the cortical regions,
whereas tubulin extended from the perinuclear region to the
cortex (our unpublished data). As expected, a small propor-
tion of vesicles, probably those that were docked at the
plasma membrane, clearly localized close to the phalloidin-
positive F-actin cortex (our unpublished data). The above-
mentioned data suggest that the expression of tail fragment
of MyoVa does not inhibit cellular membrane traffic in gen-
eral but is selective for MyoVa-associated organelles and
interferes with their F-actin–dependent transport in the cor-
tex.
Silencing of MyoVa by RNA Interference, or Expression of
the MyoVa Tail Domain, Reduces the Number of Secretory
Vesicles Docked at the Plasma Membrane, the Number of
Exocytotic Events, and Insulin Release Provoked by
Glucose
To confirm and further quantitate the change in the number
of vesicles at the cortex after inhibition of MyoVa with
MGTD.EGFP (Figures 3 and 4), we visualized vesicles
within 100 nm of the plasma membrane by using TIRF
microscopy (Axelrod, 1981; Tsuboi et al., 2000). We first
counted the number of plasma membrane-associated vesi-
cles in a 200-m2 area. This revealed that MGTD.EGFP
overexpression significantly reduced (by 52.6%) the number
of plasma membrane-docked vesicles (Figure 5, A and B).
We then counted the total number of NPY.mRFP release
events from cells expressing NPY.mRFP together with
empty plasmid (pAdTrack.CMV) or plasmid bearing MGT-
D.GFP during incubation with 50 mM KCl. The number of
NPY.mRFP release events was reduced by 86.9% in the
MGTD.EGFP-expressing cells compared with controls (Fig-
ure 5C and Fig 5avideo3.mov and Fig 5bvideo4.mov),
whereas glucose or KCl-stimulated increases in [Ca2]i were
not altered (Figure 5D).
To avoid potential nonspecific effects of overexpression of
MGTD.EGFP, and to permit measurements of insulin secre-
tion in cell populations, we used RNA interference (Elbashir
et al., 2001) to silence endogenous MyoVa expression in
MIN6 -cells (Varadi et al., 2003; Da Silva Xavier et al., 2004).
We targeted two regions of mouse MyoVa cDNA (see Ma-
terials and Methods) and found that both of the siRNA du-
plexes tested reduced the total MyoVa expression by at least
40%. However the siRNA pair corresponding to 2390–2410
base pairs was more effective and reduced the total MyoVa
expression by 55  5% with respect to a scrambled oligonu-
cleotide duplex; this siRNA was used in the experiments
presented in Figure 6. In MyoVa-silenced cells, we found
similar vesicle clustering as observed after MGTD.EGFP
expression (Figure 6B, c and d vs. a and b; n  315 cells in
five independent experiments; n  85 and 230 similar to
those of image c and d, respectively), whereas significant
clustering of LDCVs was not detected in control cells (Figure
6B, a and b, n  267 cells, in five independent experiments).
As expected from previous transfection experiments in
MIN6 cells (Varadi et al., 2002), the siRNA suppression of
MyoVa protein expression was heterogeneous (Figure 6C).
Thus, in 30–40% of the siRNA-treated cells endogenous
MyoVa protein was no longer detectable (Figure 6C, ar-
Figure 5. Blockage of MyoVa function reduces the number of
plasma membrane-docked LDCVs and depolarization-induced exo-
cytotic events. MIN6 cells were cotransfected with NPY.mRFP and
MGTD.EGFP or the empty plasmid pAdTrack.CMV and then im-
aged by TIRF microscopy (see Materials and Methods for details). (A)
Typical TIRF images of docked vesicles observed at 3 mM glucose in
control (a) and MGTD.EGFP-overexpressing cells (b). (B) The den-
sity of docked vesicles was determined by counting the vesicles in
each image (200-m2 area, n  5 cells). (C) The number of NPY.m-
RFP release events was counted for 5 min and expressed as the
percentage of the number of docked insulin vesicles. (D) [Ca2]i
changes in control (open symbol, n  158 cells in three independent
experiments) and MGTD.EGFP-expressing cells (closed symbol, n
58 cells in eight independent experiments) in response to stimula-
tion with glucose or KCl (see Supplemental Data Fig 5avideo3.mov
and Fig 5bvideo4.mov).
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rows). By contrast, in the remainder of the cells, MyoVa
expression was suppressed by 50–80%. We costained the
cells for tubulin to eliminate the possibility that the observed
reduction in MyoVa expression could be a result of uneven
immunostaining. Excluding this possibility, tubulin staining
was equally strong in the siRNA-treated cells as in control
cells.
Insulin release was measured from MyoVa-silenced and
control cells by using an insulin ELISA assay (see Materials
and Methods). To investigate the effect of reduced MyoVa
activity on the size of the readily releasable/docked vesicle
pool (Bratanova-Tochkova et al., 2002; Rutter, 2004), we
stimulated cells with KCl. Suppression of MyoVa activity
lead to a 29  3.4% decrease in the number of release events
compared with control cells (Figure 7A). Similarly, glucose-
stimulated insulin release, expected to reflect release of LD-
CVs from both a readily releasable and reserve pool, also
was significantly reduced by 28  5.7% (Figure 7B). These
data are in agreement with those obtained by TIRF imaging,
bearing in mind the heterogeneous suppression of total
MyoVa after siRNA treatment. By contrast, the total insulin
content of cells was identical under all conditions (picomoles
per 500,000 cells; untransfected, 3.35  0.11; control siRNA
transfected, 3.21 0.15; and siRNA transfected, 3.28 0.09).
DISCUSSION
MyoVa Is a Mediator of Dense Core Vesicle Movement
and Insulin Secretion
We provide here morphological and biochemical evidence
that in pancreatic -cells, a convenient neuroendocrine cell
model, MyoVa 1) associates principally with secretory gran-
ules (Figures 1 and 2) and 2) transports these within the
F-actin–rich cortex toward the plasma membrane. Thus, we
show that suppression of MyoVa activity, achieved by two
distinct means (use of a dominant-negative or RNAi) leads
to clustering of vesicles and to a reduction in their cortical
localization (Figures 3, 4, and 6 and Fig 4Acvideo1.mov).
Although similar phenomena were reported recently in
PC12 cells (Rudolf et al., 2003), the present report now pro-
vides functional data to demonstrate that changes in vesicle
Figure 6. Silencing of endogenous MyoVa.
(A) MIN6 cells were transfected with 60
pmol of anti-MyoVa or scrambled siRNAs
(see Materials and Methods). Whole cell ly-
sates were prepared 24, 48, 72, and 96 h after
transfection. The immunoblot was probed
with the anti-MyoVa antibody (1:5000),
scanned, and quantified with NIH ImageJ
software (http://rsb.info.nih.gov/ij/). Data
show mean values  SE of six independent
transfections. (B) Cells were transfected with
siRNA for 36 h then infected with phogrin.E-
GFP adenoviral construct at a multiplicity of
30–100 viral particles cell1 for a further
12 h. Imaging was performed as described in
Figure 2. (C) siRNA and control cells were
fixed and coimmunostained with a rabbit
polyclonal anti-MyoVa antibody and a
mouse monoclonal anti-tubulin antibody
and then visualized with an Alexa Fluor goat
anti-rabbit 488 (green) and an Alexa Fluor
goat anti-mouse 568 (red) secondary antibody,
respectively. Arrows and asterisk indicate cells
in which no and some MyoVa staining were
observed, respectively. Hatched boundaries
obtained from overlay with the transmitted
image of the cell indicate the cell periphery.
Bars, 5 m.
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distribution are accompanied by a significant reduction in
the number of depolarization-stimulated exocytotic events
and insulin release (Figures 5 and 7 and Fig 5avideo3.mov
and Fig 5bvideo4.mov). In this way, we show that MyoVa-
driven movements of vesicles along the cortical actin net-
work are required for the terminal stages of regulated exo-
cytosis.
In the present study, long excursions of individual LD-
CVs, likely to be dependent upon MTs (Pouli et al., 1998;
Varadi et al., 2003), were observed in both dominant-nega-
tive MyoVa tail domain-expressing (Figure 4) and siRNA-
silenced cells. This finding suggests that MT-dependent
transport is unlikely to be strongly affected by the inactiva-
tion of MyoVa. Moreover, no apparent effect of expression of
the dominant tail domain was observed on the structure and
organization of the actin or tubulin networks (our unpub-
lished data). Nevertheless, we cannot rule out the possibility
that inhibition of MyoVa may have some impact on MT-
dependent transport or structure (Weber et al., 2004). Fur-
thermore, a recent report revealed that indeed MyoVa can
mechanochemically couple MTs to F-actin in vitro (Cao et al.,
2004) and implicated the tail domain in MT binding (Cao et
al., 2004).
Role of MyoVa in Controlling Mitochondrial Movements
In contrast to the situation with LDCVs, we found no effect
of inhibiting MyoVa activity on mitochondrial morphology
or movement (Figure 4). In agreement with this observation,
mitochondrial transport was not affected in cells bearing
mutations in the genes for myosins I, II, and V (DePina and
Langford, 1999). Furthermore, shortening of the lever arm of
Myo2p, the mammalian homologue of myosin V in Saccha-
romyces cerevisiae, had no effect on mitochondrial morphol-
ogy, actin organization, or the rate of mitochondrial move-
ment in the mother cell (Boldogh et al., 1998), thus arguing
against the role of MyoVa in mitochondrial motility during
interphase. On the other hand, Myo2p mutant cells were
defective in the segregation of mitochondria (Boldogh et al.,
1998), suggesting that myosin family members may partici-
pate in mitochondrial movements under some circum-
stances, including mitosis. Furthermore, the results pre-
sented here do not support the model proposed recently by
Hajnoczky and coworkers (Yi et al., 2004) in which MyoVa
was suggested to be on mitochondrial membranes and in-
volved in the Ca2-dependent control of mitochondrial mo-
tility.
Potential Mechanisms of MyoVa Recruitment to LDVCs
The finding of actin-based motor-dependent transport of
secretory vesicles, together with previous observations
showing an MT-dependent movement of secretory vesicles
to the plasma membrane (Pouli et al., 1998; Varadi et al.,
2002, 2003), provides strong evidence for the existence of a
dual transport system used by LDCVs, which is likely to be
dependent upon the localization of the vesicle within the
cell. Evidence for such a dual transport system also has been
provided for melanosomes (Reck-Peterson et al., 2000), the
endoplasmic reticulum (Tabb et al., 1998; Reck-Peterson et
al., 2000), and phagosomes (Al Haddad et al., 2001). Indeed,
it seems that motor proteins associated with the surface of
organelles are often organized into protein complexes
(Schliwa, 1999). For example, a direct interaction between
microtubule- and actin-based transport motors has been
shown for the mouse ubiquitous kinesin heavy chain and
MyoVa (Huang et al., 1999). Although the interaction be-
tween MyoVa and kinesin heavy chain might coordinate
transport in several different ways, one appealing model
(Huang et al., 1999) proposes that MyoVa and kinesin bind
to the same cargo, as well as to each other, to form an
integrated motor complex. In this model, the activity of the
complex is tightly regulated such that only one motor in the
complex is significantly active at any given time. The evident
advantage of such a motor complex is that it may allow a
single vesicle to be transported by multiple motors and to
move on both MT and actin tracks. A vesicle thus equipped
with multiple motors might make the transition from MT to
actin filaments easily by switching between motor activities.
In MT-rich cellular domains, it seems likely that kinesin
activity would lead to long-range MT-based movement
(Pouli et al., 1998; Varadi et al., 2002, 2003), whereas in
regions such as the cellular cortex, where MTs are rare or
absent, MyoVa would take over to deliver cargo to its final
destination.
It is intriguing to ask how these complexes might be
recruited to, and regulated on, LDCVs. Whereas kinectin is
thought to mediate the binding of kinesin I to membranes
(Vallee and Sheetz, 1996), more recent reports suggest that
kinesin I binds to cargoes via a set of proteins, JIP-1, JIP-2,
and JIP-3, also involved in intracellular signaling (Bowman
et al., 2000; Verhey et al., 2001). For MyoVa, cytoplasmic
domain of synaptobrevin-synaptophysin complex has been
proposed to function as a binding partner on small synaptic
vesicles (Prekeris and Terrian, 1997). On the other hand, the
Figure 7. Suppressed expression of endog-
enous MyoVa inhibits glucose-stimulated
insulin secretion. (A and B) Insulin release
in control or anti-MyoVa siRNA-transfected
cells was assayed with an insulin ELISA kit
(see Materials and Methods). Data show mean
values  SE. The total insulin content of
cells was identical under all conditions (per
500,000 cells; control, 3.35  0.11 pmol; con-
trol siRNA transfected, 3.21  0.15; and
siRNA transfected, 3.28  0.09).
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small monomeric G protein family member Rab27a has been
implicated in the interaction between melenosomes and
MyoVa (Deacon and Gelfand, 2001) in a receptor-motor
complex including the Rab27a binding protein melanophi-
lin, a bridging protein with strong similarity to the Rab3a
effector protein rabphilin (Matesic et al., 2001).
The interaction between melanophilin and MyoVa has
been shown to be regulated by a melanocyte-specific alter-
native splicing in the tail domain of MyoVa. In MyoVa,
alternative splicing takes place between exons A and G
(Figure 1A) with four alternatively spliced isoforms contain-
ing different combinations of exons B, D, and F being iden-
tified (Huang et al., 1998a,b; Seperack et al., 1995). The pres-
ence of exon F, an alternatively spliced exon expressed in
melanocytes but not in neuroendocrine cells, is required for
MyoVa to localize to melanosomes (Seperack et al., 1995;
Nagashima et al., 2002; Wu et al., 2002b). In addition, the
globular tail domain is required for melanophilin–MyoVa
interaction (Wu et al., 2002a). In PC12 cells, overexpression
of a tail fragment containing exon F did not target to vesic-
ular structures. However, the expression of exon B was
required for the localization of MyoVa to vesicle structures
in this neuroendocrine cell (Au and Huang, 2002). In agree-
ment with these results, we found that the neuronal splice
variant containing exon B but missing exons D and F is
expressed in -cells.
Given the above, it seems likely that exon B and the
globular tail domain of MyoVa are involved in the interac-
tion with a Rab effector protein in -cells as described in
melanosomes. However, the composition of the organelle
receptor complex may well be different in the two cell types.
Thus, Rab27a and MyRIP have been implicated in the reg-
ulation of exocytosis in pancreatic -cells and neuroendo-
crine PC12 cells (Waselle et al., 2003, Desnos et al., 2003).
However, the Rab27/MyRIP protein complex does not seem
to require recruitment of myosin on the secretory granules
for function (Waselle et al., 2003). The association of myosin
Va and Rab27/MyRIP has not been demonstrated in vivo,
although it contributes to the cytoplasmic distribution of
secretory granules in PC12 cells (Rudolf et al., 2003). Might
other members of the Rab family be involved in binding
MyoVa to vesicles? Rab3a is known to be specifically asso-
ciated with small synaptic vesicles and insulin granules
(Regazzi et al., 1996) and thus may have a role, a view
supported by the fact that Rab3a/ mice develop of hyper-
glycemia and insulin secretory deficiencies (Yaekura et al.,
2003). Further studies will be necessary to distinguish be-
tween these possibilities and to explore the mechanisms
whereby increases in glucose concentration might lead to
the recruitment of MyoVa to LDCVs in insulin-secreting
cells.
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